PI3K Pathway Inhibition for Philadelphia-Like Acute Lymphoblastic Leukemia

费城样急性淋巴细胞白血病的 PI3K 通路抑制

• 批准号: 8821885
• 负责人: SARAH KATHLEEN TASIAN
• 金额: $ 16.97万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-16 至 2019-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8821885
• 关键词: ABL1 gene; Acute Lymphocytic Leukemia; Adult; Adult Acute Lymphocytic Leukemia; Advisory Committees; Aftercare; Animals; Apoptosis; Biological Assay; Biological Markers; Biometry; Blinded; Cell Death; Cells; Chemosensitization; Child; Childhood Acute Lymphocytic Leukemia; Clinic; Clinical; Clinical Research; Clinical Trials Design; Cytokine Receptors; Cytometry; Cytotoxic Chemotherapy; DNA Sequence Rearrangement; Data; Development; Developmental Therapeutics Program; Dexamethasone; Diagnostic; Discrimination; Drug Targeting; Environment; Faculty; Flow Cytometry; Foundations; Gene Expression Profile; Generations; Genomics; Goals; Health; Hematologic Neoplasms; Human; Immunoblotting; International; JAK1 gene; JAK2 gene; K-Series Research Career Programs; Laboratories; Laboratory Research; Laboratory Study; Lead; MAP Kinase Gene; Measurement; Measures; Mentors; Mentorship; Mutation; Oncogenic; Outcome; PDGFRB gene; Pathway interactions; Patients; Pediatric Hematologist/Oncologist; Pediatric Hospitals; Pediatric Oncologist; Pennsylvania; Pharmacology; Phase; Phenotype; Philadelphia; Philadelphia Chromosome; Phosphoproteins; Phosphotransferases; Physicians; Prednisone; Protein Isoforms; Proteins; Receptor Signaling; Refractory; Relapse; Reporting; Research; Residual state; Resistance; Resources; Risk; Safety; Sampling; Scientist; Signal Pathway; Signal Transduction; Signal Transduction Inhibitor; Signal Transduction Pathway; Signaling Protein; Sirolimus; Solid; Testing; Therapeutic; Toxic effect; Training; Translating; Translational Research; Treatment Failure; Universities; Up-Regulation; Vincristine; Xenograft Model; analog; asparaginase; base; biobank; burden of illness; career; chemotherapy; clinical efficacy; combinatorial; design; experience; genetic analysis; high risk; human FRAP1 protein; improved; in vivo; inhibitor/antagonist; leukemia; mTOR Inhibitor; next generation sequencing; novel; patient oriented; pre-clinical; preclinical efficacy; programs; resistance mechanism; response; skills; small molecule; tumor

 DESCRIPTION (provided by applicant): My long-term career goals are to develop better therapies, improve cure rates, and minimize toxicities for children with high-risk leukemias. My clinical experiences as a pediatric oncologist inspire the bench-based laboratory studies that will help me to achieve these goals. This mentored career development award (CDA) proposal is designed to facilitate my development as an independent translational physician-scientist via acquisition of critical laboratory skills in human leukemia xenograft models and preclinical signal transduction inhibitor testing, as well as to pursue additional didactic training in oncogenic signl transduction, cell death, pharmacology, and early phase clinical trial design and biostatistics. I will conduct the proposed studies under the outstanding mentorship of Dr. Stephan Grupp and Dr. Martin Carroll, both international leaders in translational leukemia research and experienced CDA mentors, and my multi-disciplinary Advisory Committee comprised of senior faculty with scientific and clinical expertise in hematologic malignancies. The resource-rich environment of the Children's Hospital of Philadelphia and the University of Pennsylvania provides an ideal setting in which to conduct these patient-oriented laboratory studies. We have focused upon the Philadelphia chromosome-like (Ph-like) subset of acute lymphoblastic leukemia (ALL), which comprises ≥15% of childhood and adult ALL and is associated with extremely high relapse rates and dismal long-term survival. We and others have observed constitutive activation of oncogenic cytokine receptor signaling in earlier studies of Ph- like ALL, particularly of the JAK/STAT and PI3K/Akt/mTOR pathways. While preclinical and early clinical studies of JAK inhibition in ALL are underway, therapeutic disruption of aberrant PI3K pathway signaling has not been specifically investigated in Ph-like ALL. We hypothesize that we can efficiently individualize high-risk ALL therapy by reliably identifying the Ph-like ALL phenotype by phosphoflow cytometry and can use these data for rational selection of signal transduction inhibitors for effective combinatorial therapy. During the next five years, I propose (1) to define the Ph-like ALL "phosphosignature" and to predict responses to signal transduction inhibitors, (2) to discover the most potent PI3K pathway signal transduction inhibitor in Ph-like ALL and to identify compensatory upregulation of signaling proteins as a potential mechanism of treatment failure, and (3) to determine the chemosensitization potential of PI3K pathway signal transduction inhibitor treatment in Ph-like ALL. Successful development of these laboratory and clinical research strategies will ultimately allow me to lead a translational research program in developmental therapeutics for children with clinically high-risk leukemias.

 描述（由申请人提供）：我的长期职业目标是开发更好的治疗方法，提高治愈率，并尽量减少高危白血病儿童的毒性。作为一名儿科肿瘤学家，我的临床经验激发了基于实验室的研究， 帮助我实现这些目标。这个指导职业发展奖（CDA）的建议，旨在促进我的发展，作为一个独立的翻译医生，科学家通过收购关键的实验室技能，在人类白血病异种移植模型和临床前信号 转导抑制剂测试，以及在致癌信号转导，细胞死亡，药理学和早期临床试验设计和生物统计学方面进行额外的教学培训。我将在Stephan Grupp博士和Martin卡罗尔博士的出色指导下进行拟议的研究，他们都是转化白血病研究的国际领导者和经验丰富的CDA导师，我的多学科咨询委员会由具有血液恶性肿瘤科学和临床专业知识的高级教师组成。费城儿童医院和宾夕法尼亚大学资源丰富的环境提供了一个理想的环境，在其中进行这些以病人为导向的实验室研究。我们关注的是急性淋巴细胞白血病（ALL）的费城染色体样（Ph样）亚群，该亚群占儿童和成人ALL的≥15%，与极高的复发率和令人沮丧的长期生存率相关。我们和其他人在早期的Ph样ALL研究中观察到致癌细胞因子受体信号传导的组成性激活，特别是JAK/STAT和PI 3 K/Akt/mTOR通路。虽然ALL中JAK抑制的临床前和早期临床研究正在进行中，但尚未在Ph样ALL中专门研究异常PI 3 K通路信号传导的治疗性破坏。我们假设，我们可以有效地个性化高危ALL治疗的可靠鉴定Ph样ALL表型的磷酸化流式细胞术，并可以使用这些数据合理选择信号转导抑制剂的有效组合治疗。在未来五年，我建议（1）界定 Ph样ALL“磷酸化信号”并预测对信号转导抑制剂的反应，（2）发现Ph样ALL中最有效的PI 3 K通路信号转导抑制剂并鉴定信号蛋白的代偿性上调作为治疗失败的潜在机制，和（3）确定Ph样ALL中PI 3 K通路信号转导抑制剂治疗的化学增敏潜力。这些实验室和临床研究策略的成功发展将最终使我能够领导一个转化研究项目，为临床高危白血病儿童提供发育治疗。